UK markets closed

Genpact Limited (G)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
31.53+0.64 (+2.07%)
As of 01:12PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 5.57B
Enterprise value 6.49B
Trailing P/E 9.06
Forward P/E 18.32
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.28
Price/book (mrq)2.48
Enterprise value/revenue 1.45
Enterprise value/EBITDA 8.40

Trading information

Stock price history

Beta (5Y monthly) 1.07
52-week change 3-30.88%
S&P500 52-week change 321.23%
52-week high 344.96
52-week low 329.41
50-day moving average 333.63
200-day moving average 335.18

Share statistics

Avg vol (3-month) 31.62M
Avg vol (10-day) 31.47M
Shares outstanding 5180.33M
Implied shares outstanding 6183.63M
Float 8165.88M
% held by insiders 11.01%
% held by institutions 198.98%
Shares short (28 Mar 2024) 44.42M
Short ratio (28 Mar 2024) 42.49
Short % of float (28 Mar 2024) 43.18%
Short % of shares outstanding (28 Mar 2024) 42.45%
Shares short (prior month 29 Feb 2024) 42.25M

Dividends & splits

Forward annual dividend rate 40.61
Forward annual dividend yield 41.97%
Trailing annual dividend rate 30.55
Trailing annual dividend yield 31.78%
5-year average dividend yield 41.05
Payout ratio 416.13%
Dividend date 326 Mar 2024
Ex-dividend date 408 Mar 2024
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 14.10%
Operating margin (ttm)13.96%

Management effectiveness

Return on assets (ttm)8.30%
Return on equity (ttm)30.99%

Income statement

Revenue (ttm)4.48B
Revenue per share (ttm)24.55
Quarterly revenue growth (yoy)4.00%
Gross profit (ttm)N/A
EBITDA 725.51M
Net income avi to common (ttm)631.25M
Diluted EPS (ttm)3.41
Quarterly earnings growth (yoy)224.70%

Balance sheet

Total cash (mrq)588.08M
Total cash per share (mrq)3.25
Total debt (mrq)1.5B
Total debt/equity (mrq)66.85%
Current ratio (mrq)1.43
Book value per share (mrq)12.53

Cash flow statement

Operating cash flow (ttm)490.81M
Levered free cash flow (ttm)266.21M